

Personal Statement for Nomination to the IUIS Council: Dr Sabelle Jallow

Email: sabellejallow@yahoo.com



I hereby submit my application to be considered to serve a second term on the Council of the International Union of Immunological Societies (IUIS). I have had the honor of serving as a council member, a position I truly enjoyed and have learned and collaborated with scientists across the advancement of global health.

I for the I have over 25 of experience spanning academic, clinical, and public health research, and thus I have a unique perspective grounded in science, leadership, and a passion for equity in health research and innovation. I have PhD in Molecular Virology from the University of Antwerp, preceded by an MSc in Molecular Biology (Great Distinction) and a BSc in Chemistry (Distinction). Since then, I have held progressive research and leadership roles, including Principal Medical Scientist at the National Institute for Communicable Diseases (NICD) in South Africa and Lecturer at the University of the Witwatersrand, where I have consistently advanced immunology research, education, and capacity building.

My research has contributed to vaccine development, infectious disease surveillance, antimicrobial resistance, and mycoses, with a focus on diseases disproportionately affecting low- and middle-income countries. I have led nationally and internationally funded projects—including those supported by the WHO, US CDC, and the Wellcome Trust—and have served as technical advisor and trainer to ministries of health, WHO, and Africa CDC. My work has always emphasized collaboration, capacity strengthening, and the promotion of African leadership in science.

I was a member of the executive of the Federation of African Immunological Societies (FAIS), where I have championed young investigators, supported gender equity in science, and supported dissemination of immunological research in Africa. As an active member of IUIS, I have contributed to various initiatives promoting immunology education and training across Africa. I am deeply committed to continuing this service through active engagement on the IUIS Council.

I believe the IUIS has a critical role to play in strengthening the global immunology ecosystem, particularly by ensuring representation, inclusion, and investment in immunologists from underserved regions. If elected, I will continue to support the strategic vision of IUIS in shaping immunological sciences for improved health outcomes globally. It would be a privilege to serve once more on the IUIS council, and I look forward to the opportunity to contribute my experience, insights, and passion.

Dr Sabelle Jallow (PhD)

National Institute for Communicable Diseases; Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses (CHARM); 1 Modderfontein Road, Sandringham, Johannesburg, 2192, South Africa. Phone: +27817050273 | E-mail: sabellejallow@yahoo.com; sabellej@nicd.ac.za

Education

PhD [Molecular Virology]

May '04 – Sept '08 **University of Antwerp (UA) and Institute of Tropical Medicine (ITM)** Belgium

Master of Science in Molecular Biology (Great Distinction)

Sept '01 – Sept '03 **Free university of Brussels & University of Brussels & Catholic university of Leuven** Belgium

Bachelor of Science in Chemistry (Distinction)

Sept '93 – Oct '96 **Mount St. Vincent's University** Halifax, NS, Canada

Professional Experience

May '21 – Present **University of Witwatersrand** South Africa

Lecturer

- Lecturer, Immunology (2016 – Present) Class: Honours in Molecular Medicine I & III. University of Witwatersrand, Faculty of Health Sciences. Topic: Vaccines and Immune tolerance. Innate and Adaptive Immunity
- Lecturer, University of Johannesburg (2020- Present): Class BSC Biochemistry Topic: Vaccines.
- Lecturer, Immunology (2019 - Present); Class: MSc in Vaccinology (African Leadership in Vaccinology Expertise -ALIVE). University of Witwatersrand, School of Pathology, Faculty of Health Sciences. Topic: Innate Immunity (Pattern recognition, inflammation, etc).

Nov 2020 – Present **National Institute for Communicable Diseases** South Africa

Principal Medical Scientist: Centre for Healthcare-Associated Infections, Antimicrobial Resistance & Mycoses

- **Laboratory manager:** Overall supervision and responsibility of the Centre's molecular laboratory to ensure compliance with the mandate of the National Institute for Communicable Diseases (NICD).
- Institute, design and manage public health and infectious diseases research programs.
- Project lead for a USAID grant managed by JHPEIGO to perform wastewater surveillance for Carbapenem resistant Enterobacterales (CRE) in South Africa.
- **Project lead** for a US CDC grant to increase capacity for fungal disease surveillance, identification, and characterisation and to develop a network for fungal genomic surveillance in Southern Africa.
- **Principal investigator for wastewater surveillance** for WHO high priority bacterial and fungal pathogens.
- **Lead a team of scientists** to develop a research agenda related to diseases/ conditions of interest in the Centre; publish and present research findings within the NHLS and at scientific congresses.
- Applied specialized knowledge in **molecular epidemiology, bacteriology and mycology** to perform **surveillance, outbreak response and diagnostics for healthcare and community-associated bacterial and fungal infections**.
- **Established and supported appropriate public health-focused research** into bacterial and fungal infections.
- Development and maintenance of the quality system that governs the laboratory and service components of the department to ensure compliance with the principles of Good Laboratory Practice and the fulfilment of SANAS accreditation requirements.
- Member of the NICD Institutional Biosafety and Biosecurity Committee.

- Provide expert advice to internal (NICD and NHLS) and external (Department of Health, WHO, CDC etc.) stakeholders.
- A member of expert committees related to advising and guiding the Department of Health and other professionals on issues related to above.
- Organizer and trainer: Joint National Institute for Communicable Diseases and Wellcome connecting science training on Antimicrobial Resistance of Bacterial Pathogens (9-14 March 2014).

Oct 2017 – Sept 2020

National Institute for Communicable Diseases

South Africa

Senior Medical Scientist (Centre for Vaccines and Immunology (CVI) WHO-funded position)

- **Acute flaccid paralysis and wastewater surveillance for polio viruses** and sequencing of polioviruses under high containment levels to facilitate appropriate actions for the **WHO polio eradication programme**.
- Performed research and development to assess the appropriateness of tests, to improve existing laboratory tests and to develop new tests and techniques to optimise and improve the provision of public health surveillance.
- **Quality Management of the laboratory** which involves the implementation and monitoring of systems to ensure accurate and reliable results and to **maintain accreditation by SANAS and WHO**.
- Applied specialised knowledge to **diagnose disorders, diseases and identify pathogens**, and where necessary provide consultation, so that appropriate treatment or control methods can be provided/implemented.

Oct '12 – Sept '17

Vaccines & Infectious Diseases Analytics Research Unit

South Africa

Public health Scientist (Vaccines preventable diseases)

- Performed research into vaccine preventable diseases (pneumococcus, measles, respiratory syncytial virus and the impact of HIV-infection on Transfer of antibodies from mother to infant. Also designed, developed and implemented molecular, immunological and virological assays.

Dec '12 – Dec '14

Medical Research Council (UK)

Fajara, The Gambia

HIV Immunologist (West Africa Collaboration-international post)

- **Principle Investigator** and grant recipient of EDCTP Senior fellowship for NK cell functional response project.
- Formed collaborations between stakeholders in the Gambia, Senegal, Guinea Bissau, and the United Kingdom.
- Measured immunogenicity of a series of HIV specific peptide pools for ability to elicit recall responses of NK activity and HIV vaccinated individuals and at-risk populations, including sero-discordant couples.

Mar '09 – July '12

University of Oxford (Weatherall Institute of Molecular Medicine)

Oxford, England

Post-doctoral Scientist (Cellular Immunology and Molecular Biology)

- Performed cellular immunological studies to analyse the specificity, function and HLA restriction of T-cell responses to the HIV-2 capsid; molecular genetics to study effect of human trim5alpha variation on restriction of different retroviruses; antigen processing studies to determine how different viral sequences are processed and presented to the immune system.

Feb '04 – Feb '09

Medical Research Council Laboratories

Fajara, The Gambia

Higher Scientific Officer (Viral Diseases programme)

- **Principle investigator of the HIV drug resistance study at MRC**

- Designed, Developed, assessed and implemented new assays to measure HIV drug resistance and performed research into innate resistance due to natural polymorphisms.
- Performed sequence generation and drug resistance analysis and developed an HIV-2 sequence and drug-resistance mutation database

Sept '99 – Aug'01

Medical Research Council Laboratories

Fajara, The Gambia

Scientific Officer (Immunology)

- **Laboratory manager:** HLA Typing Laboratory.
- Performed research into MHC associations with diseases of interest (HIV, Malaria, TB, Measles) and analysis and data management of all DNA Haplotyping Results.
- Used Flow cytometry to determine CD4 T-cell, CD45RO & CD45RA counts to monitor HIV disease progression.

Management experience

- **Laboratory manager:** HLA Typing Laboratory | MRC, The Gambia 1999-2001
- **Principle investigator** of the HIV drug resistance study | MRC, The Gambia 2004-9
- **Principle Investigator (EDCTP Senior fellowship)** for NK cell functional response project | MRC UK post, 2012-2014
- **Laboratory manager:** CHARM Molecular Laboratory | NICD, South Africa 2020-24
- **Project lead:** CDC funded project on Fungal genomic surveillance in the Southern African region (2021-2024)
- **Project lead:** USAID funded project that is managed by JHPiego on wastewater surveillance of carbapenem resistant Enterobacterales.

Reviewer

- **Reviewer for international journals** including Clinical Infectious Diseases, Journal of Infectious Diseases, AIDS, Infectious Diseases, Clinical Medicine Reviews in Therapeutics, HIV Medicine, Antiviral Therapy, Frontiers in Pediatrics, J. Medical Virology.
- **Expert Reviewer for grants and fellowships:** European and Developing Countries Clinical Trials Partnership (EDCTP) and Africa Research Excellence Fund (AREF).
- **Guest Editor: J. of Leucocyte Biology.**

Memberships

- **Medical Scientist** with Health Professions Council of South Africa – **MS0003638**.
- **Professional Natural Scientist** with South African Council for Natural Scientific Professions– **115302**.
- European and Developing Countries Clinical Trials Partnership (**EDCTP**) HIV working group.
- European and Developing Countries Clinical Trials Partnership (**EDCTP**) and Africa Research Excellence Fund (**AREF**) **expert reviewing committee**.
- South African Immunology Society (**SAIS**); International Society for Infectious Diseases (**ISID**); International Union of Immunological Societies (**IUIS**) **Publication committee; Council** member of International Union of Immunological Societies (**IUIS**).
- Executive member and Southern Africa representative: **Federation of African Immunology Societies (FAIS)**.
- **Africa CDC** antimicrobial resistance (AMR) Genomic Surveillance Focus Group.
- Expert Member of **Africa CDC** Research Ethics consultative group.
- Expert Member of **Africa CDC** Consultative group on the Training Curriculum and Competency framework for Public Health Genomics and Bioinformatics in Africa.
- International AIDS Vaccine Initiative (IAVI) Leadership Development Program.
- **Scientific and organizing committee:** Genomics for Antimicrobial Resistance Surveillance and One Health symposium. 15–16 March 2024, Johannesburg, South Africa.

Publications

1. **Enhancing clinical microbiology for genomic surveillance of antimicrobial resistance implementation in Africa.** Henry M Kajumbula, Daniel Gyamfi Amoako, Sofonias K Tessema, Mabel Kamweli Aworh, Francis Chikuse, Iruka N Okeke, Uduak Okomo, **Sabelle Jallow**, Beverly Egyir, Aquillah M Kanzi, Abdul Karim Sesay, Yewande Habib Alimi, Kwabena O Duedu, and Olga Perovic. Antimicrobial Resistance & Infection Control (2024) 13:135.

2. **Evaluation of Xpert Carba-R for detecting carbapenemase-producing organisms in South Africa.** Sanelisiwe T. Duze, Teena Thomas, Tshegofatso Pelego, Sabelle Jallow, Olga Perovic, Adriano Duse. African Journal of Laboratory Medicine, 05 January 2023, Vol 12, No 1 a1898.
3. **A Retrospective Analysis of Culture-Confirmed Enterococci Bloodstream Infections in South Africa, 2016-2020: A Cross-Sectional Study.** Mogokotleng R, Ismail H, Perovic O, Jallow S. Trop Med Infect Dis. 2022 Dec 27;8(1):19. doi: 10.3390/tropicalmed8010019.
4. **Acinetobacter baumannii complex, national laboratory-based surveillance in South Africa, 2017 to 2019.** Olga Perovic, Adrian Duse, Vindana Chibabhai, Marianne Black, Mohamed Said, Elizabeth Prentice, Jeannette Wadula, Yesholata Mahabeer, K Swe Swe Han, Ruth Mogokotleng, Wilhelmina Strasheim, Michelle Lowe, Sabelle Jallow, Husna Ismail, for GERM-SA. PLoS One 2022, Aug 4;17(8):e0271355.doi: 10.1371/journal.pone.0271355.
5. **Sensitivity of the acute flaccid paralysis surveillance system for poliovirus in South Africa, 2016–2019.** W Howard, S Moonsamy, L Seakamela, S Jallow, F Modiko, H du Plessis, Rosina Sibiya, Mercy Kamupira, Elizabeth Maseti, Melinda Suchard. Journal of medical microbiology 2021 Oct;70(10):001441.doi: 10.1099/jmm.0.001441.
6. **Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor.** Sabelle Jallow and Nelesh P. Govender. J. Fungi 2021;7(3):163; <https://doi.org/10.3390/jof7030163>.
7. **Clearance of Immunodeficiency-associated Vaccine-derived Poliovirus Infection With Pocapavir.** Copelyn J, Hincks JR, Wilmshurst JM, Petersen W, Howard W, Jallow S, Moonsamy S, Seakamela L, Suchard M, Collett MS, Eley B. Pediatr Infect Dis J 2020;39:435–437.
8. **Placental Transfer of Respiratory Syncytial Virus Antibody among HIV-Exposed, Uninfected Infants.** Patel SM, Jallow S, Boiditswe S, Madhi SA, Feemster KA, Steenhoff AP, Arscott-Mills T, Muthoga C, Ajibola G, Shapiro R, Shah SS, Cunningham CK, Kelly MS. J Pediatric Infect Dis Soc 2019 Sep 24. pii: piz056. doi: 10.1093/jpids/piz056.
9. **Accelerated immunodeficiency-associated vaccine derived poliovirus serotype 3 (iVDPV3) sequence evolution rate in a 3-month old boy with X-linked agammaglobulinemia and perinatal HIV exposure.** Sabelle Jallow, Jo M. Wilmshurst, Wayne Howard, Julie Copelyn, Lerato Seakamela, Koon-Wing Chan, Robert Sebunya, Rosinah Sibiya, Heleen Du Plessis, Charlene Jacobs, Natacha Berkowitz, Lucille Blumberg, Kerrigan McCarthy, Elizabeth Maseti, Mercy Kamupira, Nonhlanhla Dlamini, Nicky Gumede Ousmane M. Diop, Yu Lung Lau, Shelina Moonsamy, Brian Eley, Melinda Suchard. Clin Infect Dis. 2019 Jun 18;69(1):151-154.
10. **Impaired transplacental transfer of respiratory syncytial virus (RSV) neutralizing antibodies in HIV-infected compared to HIV-uninfected pregnant women.** Jallow S, Agosti Y, Kgagudi P, Vandecar M, Cutland CL, Simões EAF, Nunes MC, Suchard MS, Madhi SA. Clinical Infectious Diseases, Volume 69, Issue 1, 1 July 2019, Pages 151–154
11. **Possible implications of maternal HIV infection for increasing measles susceptibility in young infants.** Sabelle Jallow & Shabir A. Madhi. Future Virology, 2018, 13(6), 371-373
12. **Maternal HIV infection associated with reduced transplacental transfer of measles antibodies and increased susceptibility to disease.** Sabelle Jallow, Clare L. Cutland, Alexis K. Masbou, Peter Adrian, Shabir A. Madhi. Journal of Clinical Virology, 2017; 94 p50–56.
13. **Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions.** Sabelle Jallow, Shabir A. Madhi, Metsekae Richard Madimabe, Nadia van Niekerk, Kiran Parbhoo, Fatima Moosa, Kebashni Thandrayen, Nosisa Sipambo, Avy Violari, Udai Kala, Karen Petersen, Sanushka Naidoo, Charl Verwey, David Paul Moore and Marta C. Nunes. Vaccines. 2017 Aug 3;35(34):4321-4329
14. **Pneumococcal conjugate vaccine in HIV-infected and HIV-exposed, uninfected children.** Jallow S, Madhi SA. Expert Rev Vaccines. 2017 May;16(5):453-465
15. **The presence of prolines in the flanking region of an immunodominant HIV-2 gag epitope influences the quality and quantity of the epitope generated.** Sabelle Jallow, Aleksandra Leligdowicz, Holger B. Kramer, Clayton Onyango, Matthew Cotten, Cynthia Wright, Hilton C. Whittle, Andrew McMichael, Tao Dong, Benedikt M. Kessler and Sarah L. Rowland-Jones. Eur. J. Immunol. August 2015, Volume 45 (8): 2232–2242.
16. **HLA correlates of long-term survival in vertically infected HIV-1-positive adolescents in Harare, Zimbabwe.** Shepherd BL, Ferrand R, Munyati S, Folkard SS, Boyd K, Bandason T, Jallow S, Rowland-Jones S, Yindom L. AIDS Res Hum Retroviruses. 2015 May 1; 31(5): 504–507.
17. **Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A.** Faria NR, Hodges-Mameletzis I, Silva JC, Rodés B, Erasmus S, Paolucci S, Ruelle J, Pieniazek D, Taveira N, Treviño A, Gonçalves MF, Jallow S, Xu L, Camacho RJ, Soriano V, Goubau P, de Sousa JD, Vandamme AM, Suchard MA, Lemey P. J Gen Virol. 2012 Apr;93(Pt 4):889-99.

18. **Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings.** Kevin Peterson, **Sabelle Jallow**, Sarah L Rowland-Jones, Thushan I de Silva. AIDS research and treatment. Feb 2011: 463704
19. **Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.** **Sabelle Jallow**, Abraham Alabi, Ramu Sarge-Njie, Kevin Petterson, Christopher Akolo, Akum Aveika, Hilton Whittle, Guido Vanham, Sarah Rowland-Jones and Wouter Janssens. J Clin Microbiol. Jul 2009; 4 (7): 2200-8.
20. **Presence of a Multidrug-Resistance Mutation in an HIV-2 Variant Infecting a Treatment-Naive Individual in Caio, Guinea Bissau.** **Sabelle Jallow**, Tim Vincent, Aleksandra Leligdowicz, Thushan De Silva, Carla Van Tienen, Abraham Alabi, Ramu Sarge-Njie, Peter Aaby, Tumani Corrah, Hilton Whittle, Assan Jaye, Guido Vanham, Sarah Rowland-Jones and Wouter Janssens. Clin. Infect. Dis. Jun 2009 15;48(12):1790-3.
21. **OPINION PIECE: A Call for Randomized Controlled Trials of Antiretroviral Therapy for HIV-2 Infection in West Africa.** Geoffrey S. Gottlieb, Serge-Paul Eholié, John N. Nkengasong, **Sabelle Jallow**, Sarah Rowland-Jones, Hilton C. Whittle and Papa Salif Sow. AIDS; Oct. 2008; 22(16):2069-72.
22. **Optimization of the Oligonucleotide Ligation Assay (OLA), a Rapid and Inexpensive Test for Detection of HIV-1 Drug-Resistance Mutations, for Non-B Subtypes.** Ingrid A. Beck, Claudia Crowell, Robin Kittoe, Helba Bredell, Molefe Machaba, Carolyn Williamson, Wouter Janssens, **Sabelle Jallow**, Guido van der Groen, Yiming Shao Mini Jacob, NM Samuel, Ivette Lorenzana de Rivera, Nicole Ngo-Giang-Huong, Sharon Cassol, George Alemnji, and Lisa M. Frenkel. J. Acquir Immune Defic Syndr. Aug 2008; 48 (4) :418-27.
23. **Development and evaluation of an Oligonucleotide Ligation Assay for the detection of drug resistance associated mutations in the HIV-2 pol gene.** **Jallow S**; Kaye S; Schutten M; Brandin E; Albert J; McConkey S.J; Corrah T; Whittle H; Vanham G; Rowland-Jones S; Janssens W. J. Clin. Microbiol.; May 2007, 45(5):1565-1571.
24. **Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia.** **Jallow S**; Kaye S; Alabi A; Aveika A; Sarge-Njie R; Sabally S; Corrah T; Whittle H; Vanham G; Rowland-Jones S; Janssens W; McConkey S.J. AIDS; June 26, 2006; 20(10):1455-1458.
25. **Vigorous but Short-Term Gamma Interferon T-Cell Responses against a Dominant HLA-A*2 –Restricted Measles Virus Epitope in Patients with Measles.** Jaye A, Herbert CA, **Jallow S**, Atabani S, Klein MR, Hoogerhout P, Kidd M, Van Els CACM, Whittle HC. J of Virology 2003; 77:5014-5016

Books

1. **Sabelle Jallow** & Shmona Simpson (2015). **TRIM5 Alpha and HIV-2 Infection**. In: Hope T., Stevenson M., Richman D. (eds) Encyclopedia of AIDS. Springer, New York, NY. DOI 10.1007/978-1-4614-9610-6_47-1
2. Shmona Simpson & **Sabelle Jallow** (2016). **Interactions Between HIV-2 and Host Restriction Factors**. In: Hope T., Stevenson M., Richman D. (eds) Encyclopedia of AIDS. Springer, New York, NY. DOI 10.1007/978-1-4614-9610-6_41-2

Community engagement

1. **New vaccines on the horizon.** **Sabelle Jallow**. Immunise Today 2015; 6 (3): 4
2. **Ebola Vaccine breakthrough and new vaccines on the horizon.** **Sabelle Jallow**. Infectious Diseases Updates 2016; 5 (2): 4-5

Referees

Prof. Assan Jaye, Professor of Global Health Education and Researcher Leadership, MRC Unit, The Gambia at LSHTM. Fajara, PO Box 273. Banjul, The Gambia. +220 9910720; Assan.Jaye@lshtm.ac.uk

Emeritus Prof. Guido Vanham, Dept. Microbiology, Institute of Tropical Medicine, Nationalestraat 155, Antwerp 2000. Belgium. +32 3247 6228, gvanham@ext.itg.be

Prof. Olga Perovic. National Institute for Communicable Diseases, Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses; 1 Modderfontein Road, Sandringham, Johannesburg, 2192, South Africa. Phone: +27113866278 |mobile: 0823300895 | E-mail: olgap@nicd.ac.za.

Prof. Sarah Rowland-Jones. University of Oxford. Nuffield Department of Medicine, University of Oxford, Old Road Campus Oxford, OX3 7BNS. +44 1865 287500, sarah.rowland-jones@ndm.ox.ac.uk

Clara Hijano

From: Jagne Ya Jankey <jjagne@mrc.gm>
Sent: Thursday, 15 May 2025 16:53
To: IUIS
Subject: IUIS Council Member nomination
Attachments: IUIS council member nominee SABELLE_JALLOW.pdf

Categories: Clara

Dear IUIS Secretariat,

I wish to nominate Dr Sabelle Jallow as an IUIS Council member. Please find attached the document required for her nomination.

Kind regards,
Dr Ya Jankey Jagne
President Gambia Immunology Society

DISCLAIMER: This message is private and confidential. If you have received this message in error please notify us and remove it from your system. Any views and opinions expressed in this message are those of the individual sender and do not necessarily represent the views and opinions of Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine.

CAUTION: This email originated from outside the organisation. Do not click links or open attachments unless you recognise the sender and know the content is safe.

Clara Hijano

From: Gray, CM, Prof [cgray@sun.ac.za] <cgray@sun.ac.za>
Sent: Thursday, 3 April 2025 14:30
To: IUIS
Cc: Sabelle Jallow; Abdallah Badou
Subject: Nomination to IUIS council

Follow Up Flag: Follow up
Flag Status: Completed

Categories: Clara

Dear Secretary General

As the FAIS President, I would like to nominate Sabelle Jallow and Abdallah Badou as council members. They are currently existing Council members and wish to stand for a 2nd term.

They will compile their current CVs, along with email address as a single pdf file to send before the deadline.

They are both copied on this nomination email

Regards, Clive

Clive M Gray | BSc Hons, MSc, PhD, ASSAf

Professor, Division of Immunology | Biomedical Research Institute | Group Leader, Reproductive Immunology Research Consortium in Africa (RIRCA) | President, Federation of African Immunology Societies (FAIS) | Director of the Federation of Clinical Immunology Societies (FOCIS) Centre of Excellence at Stellenbosch University | Chair, Education Committee of the International Union of Immunology Societies (IUIS)

Faculty of Medicine and Health Sciences | PO Box 241, Francie van Zijl Drive | Cape Town 8000

Email: cgray@sun.ac.za

Tel: +27 21 938 9396



forward together
sonke siya phambili
saam vorentoe

The integrity and confidentiality of this email are governed by these terms. [Disclaimer](#)

Die integriteit en vertroulikheid van hierdie e-pos word deur die volgende bepalinge bereël. [Vrywaringsklousule](#)

CAUTION: This email originated from outside the organisation. Do not click links or open attachments unless you recognise the sender and know the content is safe.